ADC Next Generation: How Custom Synthesis of Linkers, Payloads, and Heterocyclic Scaffolds Is Powering the Antibody-Drug Conjugate Revolution
Published: July 7, 2026 | Category: Industry Insights | Reading Time: 7 min
In June 2026, the world witnessed a landmark moment: Baili Tianheng's bispecific antibody-drug conjugate (ADC), Yizekang (伦康依隆妥单抗), became the first domestically developed bispecific ADC to receive global launch approval—shipping to over 700 hospitals and pharmacies across China within just 13 days of regulatory clearance. Days later, Novartis announced its acquisition of Myricx Bio to advance next-generation ADC payloads based on N-myristoyltransferase (NMT) inhibitors. These developments, alongside a flood of ADC presentations at ASCO and AACR 2026, signal that the ADC era has arrived—and it is accelerating.
But behind every successful ADC lies an equally critical challenge: the complex custom synthesis of linkers, payloads, and heterocyclic building blocks. For pharmaceutical companies racing to advance ADC programs, access to reliable, high-quality synthesis partners has become a strategic bottleneck.
Why ADCs Are Redefining Oncology
Antibody-drug conjugates represent a paradigm shift in targeted cancer therapy. By combining the precision of monoclonal antibodies with the potency of cytotoxic payloads, ADCs deliver lethal agents directly to tumor cells while sparing healthy tissue. The clinical results are striking:
●Bispecific ADCs (e.g., Baili Tianheng's dual-targeting platform) improve tumor selectivity by recognizing two antigens simultaneously, reducing off-target toxicity and overcoming resistance mechanisms
●Dual-payload ADCs (e.g., DolBio's DR319-DP combining TOP1 inhibitors and MMAE) deliver two cytotoxic agents through a single antibody, maximizing tumor kill while minimizing dose-limiting toxicity
●Novel payloads beyond traditional microtubule inhibitors and topoisomerase inhibitors—such as NMT inhibitors (Myricx Bio), amanitin-based immuno-stimulatory payloads (CCR8-targeting ADCs), and PNU-159,682 for macrophage depletion—are expanding the therapeutic window
The numbers tell the story. The global ADC market is projected to exceed $20 billion in 2026, with over 100 candidates in active clinical development. Regulatory bodies are responding: the US FDA approved multiple new ADCs in 2025–2026, and China's NMPA fast-tracked CGT and ADC approvals through its 30-day review pathway.
The Synthesis Challenge: Why ADC Manufacturing Demands Specialized Chemistry
Despite their clinical promise, ADC molecules impose extraordinary demands on synthetic chemistry. Unlike conventional small-molecule drugs, ADC development requires mastery across three distinct domains:
1. Payload Synthesis
Cytotoxic payloads must achieve sub-nanomolar potency while maintaining chemical stability during conjugation and circulation. Common payload classes include:
●Auristatins (MMAE, MMAF): Require multi-step peptide-like synthesis with precise stereochemistry
●Camptothecin derivatives (SN-38, DXd): Complex pentacyclic lactone structures requiring specialized heterocyclic chemistry
●Duocarmycins: Cyclopropylindole-based payloads with extreme sensitivity to moisture and light
●Novel payloads: NMT inhibitors, amanitin derivatives, PNU-type benzodiazepines
Each payload class demands unique synthetic routes, purification strategies, and quality control protocols. Even minor impurities can alter drug-to-antibody ratio (DAR) and compromise safety.
2. Linker Chemistry
Linkers connect the antibody to the payload and determine the ADC's stability, pharmacokinetics, and release mechanism. The diversity of linker chemistries reflects the field's rapid evolution:
●Cleavable linkers: Valine-citrulline (Val-Cit) dipeptide linkers, disulfide linkers, acid-labile hydrazones, and protease-cleavable PABC (p-aminobenzyl carbonate) spacers
●Non-cleavable linkers: Thioether linkages (SMCC, mc), maleimide-based conjugation chemistry
●Click-chemistry linkers: Azide-alkyne cycloaddition, strain-promoted alkyne-azide click reactions (SPAAC), enabling site-specific conjugation with unprecedented precision
Developing robust linker synthesis at scale requires expertise in peptide coupling, click chemistry, and bioconjugation—capabilities that few CDMOs possess in combination.
3. Heterocyclic Building Blocks
The structural complexity of ADC payloads and linkers depends heavily on advanced heterocyclic chemistry. Key scaffolds include:
●Pyrrolo[3,2-d]pyrimidines: Core structures in kinase inhibitors and emerging payload designs
●Indoles and indazole derivatives: Found in duocarmycin-type payloads and DNA-alkylating agents
●Pyrazoles and imidazoles: Ubiquitous in linker design and payload modification
●Triazole rings: Central to click-chemistry-based conjugation strategies
Sourcing these heterocyclic building blocks in high purity and at scale is one of the most persistent challenges in ADC drug development.
Beixinke Chem: Proven Heterocyclic Chemistry Expertise for the ADC Era
At Beixinke Chem, we have built our capabilities around exactly the type of complex synthesis that ADC programs demand. Our 20+ years of experience in heterocyclic chemistry, chiral synthesis, and multi-step organic synthesis positions us as a specialized partner for ADC intermediate and building block supply.
In-Stock Heterocyclic Scaffolds Relevant to ADC Programs
| Compound | CAS | Stock | Relevance |
|---|---|---|---|
| 5H-Pyrrolo[3,2-d]pyrimidine derivative | 2877704-17-9 | 68 g | Pyrrolopyrimidine scaffold — key building block for kinase-targeting payloads and linker design |
| 5-Iodo-1H-indole-3-carboxylic acid | 1190847-04-1 | 10g | Halogenated indole — versatile intermediate for indole-based payload synthesis (duocarmycin-type) |
| 4H-Pyrrolo[1,2-c][1,2,3]triazole-3-carboxylic acid | 1780654-45-6 | 10g | Pyrrolo-triazole core — directly applicable to click-chemistry linker construction |
| Multiple pyrazole derivatives | / | 40g | Pyrazole ring — fundamental scaffold in linker spacers, payload modification, and conjugation chemistry |
| Imidazo[1,5-a]pyrazine derivatives | 1160248-16-7 | 10g | Fused imidazo-pyrazine — emerging scaffold in targeted therapeutic intermediates |
| Indole-2-carboxylic acid derivatives | 69808-71-5 | 10g | Indole carboxamide — building block for DNA-intercalating payload development |
Core Capabilities
Heterocyclic Chemistry at Scale
Our team has synthesized over 1,000 complex heterocyclic compounds spanning pyrazolo[1,5-a]pyridines, tetrahydroisoquinolines, phthalazinones, carbazoles, benzothiophenes, and fused-ring systems. These capabilities directly translate to ADC payload and linker intermediate synthesis.
Click Chemistry and Conjugation-Ready Intermediates
With demonstrated synthesis of azide-containing, alkyne-functionalized, and triazole-based compounds, we provide the building blocks essential for next-generation site-specific ADC conjugation technologies.
Chiral Synthesis and Resolution
Many ADC payloads and linkers contain stereogenic centers that must be maintained with high fidelity. Our capabilities in asymmetric synthesis, chiral resolution, and Evans auxiliary chemistry ensure enantiomerically pure intermediates.
Scale-Up from Milligram to Kilogram
Whether you need milligram quantities for discovery-stage screening or kilogram batches for clinical manufacturing, our processes are designed for seamless scale-up with consistent quality and full analytical documentation (HPLC, NMR, MS, elemental analysis).
Our Custom Synthesis Workflow for ADC Intermediates
1.Structure Submission: Share your target molecule, CAS number, or structural requirements
2.Feasibility Report: Our chemists evaluate synthetic routes and provide a preliminary quotation within 24 hours
3.Route Optimization: For novel intermediates, we develop and validate robust synthetic routes before scale-up
4.Pilot Delivery: Initial gram-to-100g quantities for biological testing and process validation
5.Commercial Scale-Up: Seamless transition to kilogram scale with process validation and full analytical documentation
6.Long-Term Supply: Ongoing manufacturing with consistent quality, competitive pricing, and reliable delivery
All projects are protected under standard CDA/NDA agreements. Quality systems are ISO-certified.
Looking Ahead: The ADC Supply Chain Opportunity
The ADC field is undergoing a structural transformation. As bispecific ADCs, dual-payload designs, and novel mechanisms (NMT inhibition, immune-stimulatory payloads, TME-targeting ADCs) move from concept to clinic, the demand for specialized synthesis of linkers, payloads, and heterocyclic building blocks will intensify.
Pharmaceutical companies that secure reliable custom synthesis partnerships today will be best positioned to accelerate their ADC programs tomorrow. With a proven track record in complex heterocyclic chemistry, in-stock availability of key ADC-relevant scaffolds, and demonstrated capability from milligram to kilogram scale, Beixinke Chem is ready to support your ADC pipeline from discovery through clinical supply.
Ready to discuss your ADC synthesis needs?
📧 contact@beixinkechem.com
🌐 www.beixinkechem.com
📞 +86 139 4909 2794
About Beixinke Chem
Beixinke Chem is a specialized pharmaceutical intermediate manufacturer headquartered in China, serving global pharmaceutical and biotech partners with 20+ years of synthesis experience. We specialize in heterocyclic intermediates, chiral building blocks, click chemistry reagents, and custom synthesis for complex small-molecule programs including ADC linker-payload systems. Our 1,000+ delivered products and ISO-certified quality systems have earned the trust of 50+ partners worldwide.
No molecule is too hard—only routes yet to be disassembled.